Last updated: February 21, 2026
What is NDC 69452-0228?
NDC 69452-0228 corresponds to Kymriah (tisagenlecleucel), a CAR T-cell immunotherapy developed by Novartis. Approved by the FDA in August 2017, Kymriah treats certain blood cancers, specifically:
- Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients up to age 25
- Adult relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy
The therapy involves modifying a patient’s T-cells to target cancer cells.
Market Landscape Overview
| Segment |
Details |
| Targeted Diseases |
Pediatric and young adult ALL, LBCL |
| Market Size (Prevalence) |
Approximately 600 patients annually in the U.S. for ALL; 8,000+ for LBCL |
| Approved Indications |
FDA approvals as of 2023, expanding indications since initial approval |
| Manufacturers |
Novartis |
| Competitors |
Gilead’s Yescarta (axicabtagene ciloleucel), Kymriah’s primary competition |
Market Trends & Drivers
- Therapy Expansion: Ongoing FDA approvals for additional lymphomas and multiple myeloma variants expand potential patient base.
- Pricing and Reimbursement: Kymriah’s list price is approximately $475,000 per treatment, with post-infusion costs potentially reaching $500,000+.
- Reimbursement Landscape: CMS and private insurers are increasingly accommodating CAR T costs, supported by value-based care arrangements.
- Manufacturing Challenges: Complex logistics and individualized manufacturing drive high costs and limit supply flexibility.
- Market Penetration: High efficacy in targeted populations ensures steady adoption, but high costs and resource intensity limit broader use.
Price Projections (2023–2028)
| Year |
Estimated Average Price |
Key Assumptions |
| 2023 |
$475,000 – $500,000 |
Stable list price; inflation-adjusted; increased volume with expanded indications |
| 2024 |
$470,000 – $490,000 |
Slight price adjustments due to market dynamics and negotiations |
| 2025 |
$460,000 – $480,000 |
Price containment via competitive pressure and reimbursement negotiations |
| 2026 |
$450,000 – $470,000 |
Potential price reductions with new biosimilar or alternative therapies emerge |
| 2027 |
$440,000 – $460,000 |
Price stabilization or gradual decline as alternative therapies develop |
| 2028 |
$430,000 – $450,000 |
Continued pressure from pricing reforms and delisting of high-cost therapies |
Note: Price adjustments based on negotiated discounts, value-based arrangements, and market competition.
Regulatory and Policy Impacts
- Pricing Reforms: U.S. legislative efforts could influence therapy pricing, including value-based agreements.
- FDA Expansion: Broader approval for additional indications could elevate revenue, possibly impacting prices.
- Cost Management Initiatives: Payers may push for outcome-linked reimbursement or capitation models affecting the therapy’s market price.
Revenue Potential
| Year |
Estimated Revenue (U.S. Market) |
Assumptions |
| 2023 |
~$300 million |
600 patients at $500,000 each |
| 2024 |
~$330 million |
660 patients, moderate price decrease |
| 2025 |
~$340 million |
Slight volume increase, price containment |
| 2026 |
~$330 million |
Stabilized patient volume, further price drops |
| 2027 |
~$310 million |
Slight decline with market saturation |
| 2028 |
~$300 million |
Market maturity reduces growth |
Key Challenges & Opportunities
- Reimbursement Pressure: Willingness of payers to cover high-cost therapies depends on demonstrated value and outcomes.
- Manufacturing Costs: Innovations to reduce production costs could help lower prices.
- Pipeline Development: New therapies entering the market may erode Kymriah’s share.
- Global Expansion: Entry into international markets offers growth but involves regulatory hurdles.
Summary & Conclusions
Kymriah's pricing remained stable since launch, around $475,000, reflecting the high manufacturing, logistics, and regulatory costs associated with CAR T-cell therapies. Price projections suggest gradual declines influenced by competitive pressures and reimbursement landscape shifts. The therapy's high efficacy sustains demand but limits pricing flexibility. Future growth depends on expanding indications, international market penetration, and leveraging manufacturing innovations.
Key Takeaways
- NDC 69452-0228 (Kymriah) has a stable initial price (~$475,000) with expectations of slight decreases over five years.
- Market growth hinges on expanded indications and international adoption.
- Reimbursement strategies and policy reforms will shape future pricing and revenue.
- Competition from rival CAR T therapies influences market share and pricing potential.
- Cost reduction via manufacturing efficiencies could support more favorable pricing scenarios.
FAQs
1. What factors could lead to significant price reductions for Kymriah?
Introduction of biosimilars or alternative therapies, reimbursement reforms emphasizing cost containment, and manufacturing cost reductions.
2. How does the price of Kymriah compare to competitors?
Yescarta (Gilead) lists at approximately $373,000, slightly lower, but actual negotiated prices often closer, reflecting competitive pricing strategies.
3. Are there indications for Kymriah beyond current approvals?
Research is ongoing for additional indications such as multiple myeloma and other hematologic malignancies, which could expand market size and demand.
4. What is the U.S. market penetration forecast?
Steady increase in patient numbers through expanded indications, with growth starting to plateau as the market matures post-2025.
5. How might international markets impact future revenue?
Global markets offer growth but face regulatory, reimbursement, and logistical challenges, potentially delaying or limiting adoption.
References
[1] U.S. Food and Drug Administration (FDA). (2017). Kymriah (tisagenlecleucel) Approval Letter. Retrieved from https://www.fda.gov
[2] Novartis. (2023). Kymriah Price and Reimbursement Policy. Retrieved from https://www.novartis.com
[3] IQVIA. (2022). CAR T-cell therapy market analysis. Retrieved from https://www.iqvia.com
[4] CMS.gov. (2022). Medicare Reimbursement Policies for Oncology Drugs. Retrieved from https://www.cms.gov
